(0%) 0 points
(0%) 0 points
(0%) 0 points
(0%) $0
(0%) $0
(0%) $0
(0%) $0
(0%) $0
(0%) $0
(0%) $0
(0%) $0
(0%) $0
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 11.20%
Live Chart Being Loaded With Signals
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases...
Stats | |
---|---|
本日の出来高 | 0 |
平均出来高 | 0 |
時価総額 | 0 |
EPS | $0 ( 2024-03-12 ) |
次の収益日 | ( $-0.190 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Aligos Therapeutics, Inc. 相関
10 最も負の相関 | |
---|---|
GEEX | -0.92 |
FXCO | -0.918 |
LDHA | -0.917 |
NESR | -0.914 |
TCVA | -0.911 |
ALOR | -0.911 |
TBSA | -0.909 |
VLAT | -0.909 |
AHRN | -0.908 |
LGAC | -0.908 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Aligos Therapeutics, Inc. 財務諸表
Annual | 2023 |
収益: | $15.53M |
総利益: | $12.46M (80.24 %) |
EPS: | $-1.360 |
FY | 2023 |
収益: | $15.53M |
総利益: | $12.46M (80.24 %) |
EPS: | $-1.360 |
FY | 2022 |
収益: | $13.91M |
総利益: | $10.23M (73.57 %) |
EPS: | $-2.25 |
FY | 2021 |
収益: | $4.36M |
総利益: | $4.36M (100.00 %) |
EPS: | $-3.22 |
Financial Reports:
No articles found.
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。